OBJECTIVE: This study aims to examine the associations between musculoskeletal pain and health-related quality of life (HR-QOL) among breast cancer patients on aromatase inhibitors (AIs) and women without a history of breast cancer. METHODS: A cross-sectional study was conducted among 68 breast cancer patients on AIs for an average of 3.5 years and 137 postmenopausal women without a history of cancer. Musculoskeletal pain was assessed using a 10-cm visual analog scale; HR-QOL was examined using the Medical Outcomes Study Short Form (SF-36) health survey. Linear regression was used to estimate the associations between pain and HR-QOL in both groups. RESULTS: Approximately 64 % of the breast cancer patients and women in the comparison group reported musculoskeletal pain. Among women with breast cancer, those with pain had significantly lower HR-QOL scores in the physical (52.2 vs. 42.6; p < 0.001) and mental (52.7 vs. 45.5; p = 0.01) component summary scores compared with those without pain. In the comparison group, pain was associated with significantly lower scores in the physical (55.4 vs. 46.0; p < 0.001), but not the mental, component summary score (52.1 vs. 52.4; p = 0.82). The significant associations between pain and HR-QOL persisted after confounder adjustment in both groups. Among women with similar severity of pain, breast cancer patients reported significantly lower HR-QOL in the mental summary component compared with the women in the comparison group. CONCLUSIONS: Among breast cancer patients, musculoskeletal pain adversely affects both mental and physical components of HR-QOL. Preventing or treating AI-associated musculoskeletal pain may improve overall HR-QOL among breast cancer patients treated with AIs.
OBJECTIVE: This study aims to examine the associations between musculoskeletal pain and health-related quality of life (HR-QOL) among breast cancerpatients on aromatase inhibitors (AIs) and women without a history of breast cancer. METHODS: A cross-sectional study was conducted among 68 breast cancerpatients on AIs for an average of 3.5 years and 137 postmenopausal women without a history of cancer. Musculoskeletal pain was assessed using a 10-cm visual analog scale; HR-QOL was examined using the Medical Outcomes Study Short Form (SF-36) health survey. Linear regression was used to estimate the associations between pain and HR-QOL in both groups. RESULTS: Approximately 64 % of the breast cancerpatients and women in the comparison group reported musculoskeletal pain. Among women with breast cancer, those with pain had significantly lower HR-QOL scores in the physical (52.2 vs. 42.6; p < 0.001) and mental (52.7 vs. 45.5; p = 0.01) component summary scores compared with those without pain. In the comparison group, pain was associated with significantly lower scores in the physical (55.4 vs. 46.0; p < 0.001), but not the mental, component summary score (52.1 vs. 52.4; p = 0.82). The significant associations between pain and HR-QOL persisted after confounder adjustment in both groups. Among women with similar severity of pain, breast cancerpatients reported significantly lower HR-QOL in the mental summary component compared with the women in the comparison group. CONCLUSIONS: Among breast cancerpatients, musculoskeletal pain adversely affects both mental and physical components of HR-QOL. Preventing or treating AI-associated musculoskeletal pain may improve overall HR-QOL among breast cancerpatients treated with AIs.
Authors: Phuong Khanh Morrow; Anita C Broxson; Mark F Munsell; Karen Basen-Enquist; Carol K Rosenblum; Leslie R Schover; Lynne H Nguyen; Limin Hsu; Lilibeth Castillo; Karin M Hahn; Jennifer K Litton; Danielle N Kwiatkowski; Gabriel N Hortobagyi Journal: Clin Breast Cancer Date: 2013-10-25 Impact factor: 3.225
Authors: Nancy K Janz; Mahasin S Mujahid; Sarah T Hawley; Jennifer J Griggs; Amy Alderman; Ann S Hamilton; John Graff; Steven J Katz Journal: J Cancer Surviv Date: 2009-09-16 Impact factor: 4.442
Authors: Jack Cuzick; Ivana Sestak; Michael Baum; Aman Buzdar; Anthony Howell; Mitch Dowsett; John F Forbes Journal: Lancet Oncol Date: 2010-11-17 Impact factor: 41.316
Authors: Mitch Dowsett; Jack Cuzick; Jim Ingle; Alan Coates; John Forbes; Judith Bliss; Marc Buyse; Michael Baum; Aman Buzdar; Marco Colleoni; Charles Coombes; Claire Snowdon; Michael Gnant; Raimund Jakesz; Manfred Kaufmann; Francesco Boccardo; Jon Godwin; Christina Davies; Richard Peto Journal: J Clin Oncol Date: 2009-11-30 Impact factor: 44.544
Authors: Kirsten A Nyrop; Leigh F Callahan; Christine Rini; Mary Altpeter; Betsy Hackney; Amy DePue; Anne Wilson; Arielle Schechter; Hyman B Muss Journal: Support Care Cancer Date: 2016-01-12 Impact factor: 3.603
Authors: Julie K Silver; Vishwa S Raj; Jack B Fu; Eric M Wisotzky; Sean Robinson Smith; Rebecca A Kirch Journal: Support Care Cancer Date: 2015-08-28 Impact factor: 3.603
Authors: Clémentine Lopez; Cécile Charles; Pascal Rouby; Diane Boinon; Sophie Laurent; Annie Rey; Marc Spielmann; Sarah Dauchy Journal: Support Care Cancer Date: 2015-04-17 Impact factor: 3.603
Authors: Daniel L Hertz; Karen Lisa Smith; Yuhua Zong; Christina L Gersch; Andrea M Pesch; Jennifer Lehman; Amanda L Blackford; N Lynn Henry; Kelley M Kidwell; James M Rae; Vered Stearns Journal: Front Genet Date: 2021-06-15 Impact factor: 4.599